New diabetes clinical trial: Replication of the SEPRA Diabetes Trial in Healthcare Claims Data
Published on: October 13, 2022 at 11:00AM
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: New use of semaglutide injection; Drug: New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
Sponsor: Brigham and Women's Hospital
Active, not recruiting
https://ift.tt/O1w35k8
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: New use of semaglutide injection; Drug: New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
Sponsor: Brigham and Women's Hospital
Active, not recruiting
https://ift.tt/O1w35k8
Comments
Post a Comment